HOUSTON, Feb. 23, 2016 /PRNewswire/ -- Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with Baylor Miraca Genetics Laboratories (BMGL), a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services. The two companies, both commercial endeavors of Baylor College of Medicine, are leveraging the scientific acumen and research infrastructure from the renowned College that founded them. Each company will provide access to the services of the other for customers interested in a greater understanding of the host-microbiome relationship.
According to Cynthia Sheridan, Diversigen President, "Our pharmaceutical customers have expressed an interest in correlating microbiome data with specific host genetic traits to better understand the host-microbiome relationship as a factor in disease and in the search for more effective therapies. This partnership with BMGL will allow us to provide broader services resulting in deeper insights into human health and disease."
“Partnering with Diversigen gives us a tremendous opportunity to extend our reach into new markets, while maintaining a very clear and aligned path towards improving patient health around personalized medicine,” said Gary Huff, Baylor Miraca President and CEO.
Diversigen provides comprehensive microbiome and metagenomic services, including customized and complex data analysis, focused on solutions to improve human and animal health, environmental conditions, and agriculture production worldwide. The company is a BCM Technologies, Inc. portfolio company. Building on research conducted at the Alkek Center for Metagenomics and Microbiome Research at Baylor College of Medicine, Diversigen has years of experience, flexible sequencing, and massive bioinformatics capacity with highly diverse microbiome sample types. For more information, visit www.diversigen.com.
About Baylor Miraca Genetics Laboratories
Baylor Miraca Genetics Laboratories (BMGL) is a joint venture between Miraca Holdings and the Baylor College of Medicine, specializing in the development and commercialization of the highest quality genetic and genomic testing. BMGL offers a broad range of testing from traditional cytogenetics to chromosomal microarray analysis and next generation sequencing. Located in Houston's Texas Medical Center, BMGL offers over 4,000 tests using the latest, cutting edge diagnostic equipment to efficiently generate the most accurate clinical genetic data. www.bmgl.com
Gwynneth Ballentine, PhD MBA
Director, Scientific Operations
SOURCE Diversigen, Inc.